title: Heterogeneity of presynaptic muscarinic receptors involved in modulation of transmitter release.
abstract: In order to extend the characterization of muscarinic receptors at presynaptic sites their inhibitory effect on the stimulation-evoked release of [3H]noradrenaline and [3H]acetylcholine from different axon terminals was studied and the dissociation constants and potencies of different antagonists were estimated, in guinea-pig and rat. While oxotremorine reduced the release of [3H]acetylcholine and [3H]-noradrenaline in a concentration-dependent manner from different release sites (Auerbach plexus, noradrenergic neurons in the right atrium, cerebral cortex), McN-A 343, an M1 receptor agonist, enhanced their release evoked by field stimulation. When the inhibitory effect of oxotremorine on transmitter release was studied, pancuronium, pirenzepine and atropine were competitive antagonists of presynaptic muscarinic receptors located on the noradrenergic axon terminals of the atrium. While atropine and pirenzepine inhibited the muscarinic receptors of cholinergic axon terminals in the Auerbach plexus, pancuronium and gallamine had a very low affinity. Significant differences were found in the affinity constants of antagonists for muscarinic receptors located in the cholinergic axon terminals of Auerbach plexus and cerebral cortex, and noradrenergic axon terminals of the atrium. While atropine and pirenzepine exerted similar effects on these presynaptic sites, pancuronium, gallamine and (11-(2-[diethylamino)-methyl)-1-piperidinyl)acetyl)-5, 11-dihydro-6(1-pyrido(2,3-b)(1,4)-benzodiazepin-6-on) were much more effective on muscarinic receptors controlling acetylcholine release from the cerebral cortex and noradrenaline release from the heart. There was more than 100-fold (2.0 pA2 units) difference in affinities of these antagonists.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pharmacology, Hungarian Academy of Sciences, Budapest.
authors.forename: E S
authors.initials: ES
authors.lastname: Vizi
authors.forename: O
authors.initials: O
authors.lastname: Kobayashi
authors.forename: A
authors.initials: A
authors.lastname: Töröcsik
authors.forename: M
authors.initials: M
authors.lastname: Kinjo
authors.forename: H
authors.initials: H
authors.lastname: Nagashima
authors.forename: N
authors.initials: N
authors.lastname: Manabe
authors.forename: P L
authors.initials: PL
authors.lastname: Goldiner
authors.forename: P E
authors.initials: PE
authors.lastname: Potter
authors.forename: F F
authors.initials: FF
authors.lastname: Foldes
mesh_terms: D000320:Adrenergic Fibers / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects / Q000502:physiology*; D002799:Cholinergic Fibers / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects / Q000294:innervation* / Q000502:physiology; D008297:Male; D018727:Muscarinic Antagonists; D009130:Muscle, Smooth / Q000187:drug effects / Q000294:innervation* / Q000502:physiology; D010095:Oxotremorine / Q000494:pharmacology*; D010276:Parasympatholytics / Q000494:pharmacology; D011976:Receptors, Muscarinic / Q000145:classification / Q000502:physiology*; D009435:Synaptic Transmission / Q000187:drug effects*
chemical_list: D018727:Muscarinic Antagonists; D010276:Parasympatholytics; D011976:Receptors, Muscarinic; D010095:Oxotremorine